GeneDx Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Significant expansion efforts are underway to move advanced genetic testing from niche expert use to broader pediatric, NICU, and prenatal markets, supported by dedicated sales teams and new customer experience tools. Education, payer coverage, and tailored engagement are key to driving adoption and utilization.
-
Achieved strong growth in 2025 with $427M revenue and 70%+ margins, expanding into new markets and leveraging the industry-leading Infinity database. Early diagnosis and precision medicine remain central, with investments in technology, sales, and global reach supporting continued profitability and patient impact.
Fiscal Year 2025
-
Q4 2025 saw 27% revenue growth and 71% gross margin, driven by exome/genome testing and market expansion. 2026 guidance projects $540M–$555M revenue and 33%–35% volume growth, with major investments in sales and R&D to capture new markets and sustain profitability.
-
Rare disease genomics is rapidly expanding due to improved technology, data assets, and supportive guidelines. Market leadership is reinforced by a robust data moat, FDA breakthrough status, and strategic expansion into NICU, pediatric, and international markets.
-
Strong growth continues with expanded clinical guidelines, rapid rare disease diagnosis, and increased pediatrician outreach. Payment rates and margins are improving, with automation and payer engagement supporting profitability. Ongoing investments target new markets and operational efficiency.
-
The company is leveraging a vast genetic and phenotypic data asset to accelerate rare disease diagnosis, expand into newborn screening, and drive adoption among general pediatricians through education and simplified ordering. Market expansion is supported by improved reimbursement rates and legislative advocacy, with a shift toward genome testing expected over the next few years.
-
Q3 revenue grew 52% year-over-year to $116.7M, with exome/genome revenue up 66%. Guidance for 2025 was raised, driven by strong core growth, expanding NICU and international markets, and new Medicaid coverage in California. Adjusted gross margin reached 74%.
-
Rare disease genetic testing is expanding rapidly, with significant market leadership driven by a vast, diverse data asset and rapid, accurate diagnostics. Growth is focused on specialist and pediatrician adoption, newborn screening, and automation, while payer coverage and reimbursement continue to improve.
-
A unique data asset and rapid genome interpretation drive leadership in rare disease diagnostics, with expansion into general pediatrics accelerated by new guidelines. NICU integration, new test indications, and the Fabric Genomics acquisition support growth and international reach.
-
A leading genomics company is driving early rare disease diagnosis in pediatrics, leveraging a vast, diverse data asset and rapid sequencing technology. Strong Q2 growth, expanding reimbursement, and new AI tools support its push into NICU and general pediatrics, with future plans for international and adult markets.
-
Q2 2025 revenue surged 49% year-over-year to $102.7 million, with Exome and Genome revenue up 69% and adjusted gross margin at a record 71%. Guidance for 2025 was raised, driven by core growth, new indications, and expanding payer coverage, while profitability and cash reserves remain strong.
-
GeneDx leverages the largest rare disease data asset in the U.S. to drive rapid, accurate diagnoses, focusing on pediatric and NICU markets with high growth potential. Operational efficiency, expanding reimbursement, and a robust commercial strategy support profitability and future data monetization.
-
Early rare disease diagnosis is being prioritized through expanded genetic testing, new indications, and NICU initiatives. Financial performance is strong, with positive adjusted EBITDA and improved margins, while strategic M&A and automation are set to drive future growth.
-
Q1 2025 revenue reached $87.1M, with exome/genome revenues up 62% year-over-year and adjusted gross margin at 69%. Guidance for 2025 was raised, profitability continues, and the Fabric Genomics acquisition is set to expand AI-driven offerings and recurring revenue.
-
Significant growth is projected with over 30% volume and revenue increases, driven by expanded NICU and outpatient initiatives, rapid testing, and a robust data asset. The company maintains market leadership through clinical excellence, automation, and payer engagement, with a vision to broaden access and utility in genetic diagnostics.
-
The company is driving early genetic disease diagnosis with industry-leading exome/genome testing, supported by a vast data asset and strong clinical guidelines. FY2024 saw 54% revenue growth and margin expansion, with AI and automation set to further improve efficiency and accessibility.
Fiscal Year 2024
-
Record 2024 results featured 101% exome/genome revenue growth, 70% gross margin, and strong profitability. 2025 guidance targets $350–$360M revenue, 30%+ volume growth, and continued margin expansion, with new products and expanded sales force driving future gains.
-
Focused on pediatric genetic disease diagnosis, the company streamlined operations to prioritize exome and genome testing, achieving strong growth and high margins. AI and automation are enhancing diagnostic yield, while improved reimbursement and policy changes could further expand the market.
-
Consistent execution has driven profitability, revenue growth, and market leadership in pediatric genetic testing. Expanded Medicaid coverage, new biopharma partnerships, and automation initiatives are fueling further growth, with ambitions to make genetic testing standard at birth.
-
Q3 2024 saw 52% revenue growth year-over-year, record profitability, and gross margin expansion to 64%. Full-year guidance was raised, with strong momentum in exome/genome testing, expanding market share, and continued operational discipline.
-
Celebrating 25 years, the company has transformed its operations, doubled exome volumes, and improved gross margins to over 62%, nearing profitability. A robust data asset and expanding payer coverage support market leadership, with future growth focused on newborn screening and automation.
-
Q2 2024 saw 52% revenue growth year-over-year, margin expansion to 62%, and a narrowed net loss. Exome/genome tests drove results, with raised 2024 guidance and profitability expected in 2025. Medicaid and payer coverage, new partnerships, and operational efficiencies support continued momentum.
-
Key initiatives include expanding whole exome/genome testing, integrating with Epic for streamlined provider access, and focusing on data-driven strategies. Operational improvements and test menu rationalization are driving margin gains, with further growth expected as reimbursement expands and the data business matures.
-
The company has completed a major transformation, focusing on high-margin exome and genome testing, with strong Q1 results and a clear path to profitability in 2025. Strategic initiatives include expanding biopharma partnerships, growing NICU and newborn screening programs, and leveraging regulatory changes.